Mutant p53 murine oviductal epithelial cells induce progression of high-grade serous carcinoma and are most sensitive to simvastatin therapy in vitro and in vivo.

Madison Pereira, Alice Glogova, Jacob Haagsma, Julia Stewart, Trevor G Shepherd, Jim Petrik

Open access · goldAbstract read

In one paragraph

Article in Journal of ovarian research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 30% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

Identification of integrated stress response-related prognostic genes in high-grade serous ovarian cancer using Mendelian randomization, single-cell RNA sequencing, and bulk RNA sequencing.Frontiers in oncology · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Madison PereiraDepartment of Biomedical Sciences, University of Guelph, Guelph, ON, N1G 2W1, Canada.

Alice GlogovaDepartment of Biomedical Sciences, University of Guelph, Guelph, ON, N1G 2W1, Canada.

Jacob HaagsmaThe Mary & John Knight Translational Ovarian Cancer Research Unit, London Regional Cancer Program, London, ON, Canada.

Julia StewartDepartment of Biomedical Sciences, University of Guelph, Guelph, ON, N1G 2W1, Canada.

Trevor G ShepherdThe Mary & John Knight Translational Ovarian Cancer Research Unit, London Regional Cancer Program, London, ON, Canada.

Jim PetrikDepartment of Biomedical Sciences, University of Guelph, Guelph, ON, N1G 2W1, Canada. jpetrik@uoguelph.ca.

University of Guelph · CAWestern University · CA

Funding

CIHR 450209

6 · The paper itself

Abstract

High-grade serous carcinoma (HGSC) is the most common and aggressive subtype of epithelial ovarian cancer, characterized by gain-of-function TP53 mutations originating in the fallopian tube epithelium. Therapeutic intervention occurs at advanced metastatic disease, due to challenges in early-stage diagnosis, with common disease recurrence and therapy resistance despite initial therapy success. The mevalonate pathway is exploited by many cancers and is potently inhibited by statin drugs. Statins have shown anti-cancer activity in many, but not all cancers. Here, we investigated the role of p53 status in relation to mevalonate pathway signaling in murine oviductal epithelial (OVE) cells and identified OVE cell sensitivity to statin inhibition. We found that p53

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsOvarian NeoplasmsAnimalsCarcinoma, Ovarian EpithelialEpithelial CellsFallopian TubesFemaleHumansMevalonic AcidMiceSimvastatinTumor Suppressor Protein p53Hydroxymethylglutaryl-CoA Reductase InhibitorsMevalonic AcidSimvastatinTumor Suppressor Protein p53Fallopian tube orthotopic modelMevalonate pathwayOvarian cancerp53Simvastatin

Identifiers

PMID37986175

DOI10.1186/s13048-023-01307-x

PMCPMC10662458

OpenAlexW4388824923

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.